Man Group plc Sells 24,377 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Man Group plc decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 40.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,144 shares of the biopharmaceutical company's stock after selling 24,377 shares during the quarter. Man Group plc's holdings in Regeneron Pharmaceuticals were worth $25,746,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of REGN. Capital International Investors grew its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after purchasing an additional 155,369 shares in the last quarter. Dodge & Cox grew its stake in shares of Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after acquiring an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after buying an additional 810,144 shares during the period. Finally, Franklin Resources Inc. grew its position in Regeneron Pharmaceuticals by 7.9% during the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after buying an additional 149,124 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $2.22 on Monday, reaching $596.54. The stock had a trading volume of 666,223 shares, compared to its average volume of 789,443. Regeneron Pharmaceuticals, Inc. has a 12 month low of $520.50 and a 12 month high of $1,211.20. The firm has a market capitalization of $64.41 billion, a price-to-earnings ratio of 15.58, a P/E/G ratio of 2.34 and a beta of 0.43. The firm's 50-day moving average is $599.96 and its two-hundred day moving average is $681.90. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the company earned $9.55 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating for the company in a research note on Wednesday, April 30th. Bernstein Bank dropped their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $890.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.